At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
3'-Deoxy-3'-18F-fluorothymidine Positron Emission Tomography ([18F] FLT-PET) for the Prediction of Response to Regorafenib in the Metastatic Colorectal Cancer Patients Who Progressed After All Standard Therapies
In Brief
A clinical study evaluating Regorafenib, [18F]FLT-PET, and 1 other intervention for Colorectal Cancer. Completed, enrolled 68 participants across 1 site.
Detailed Summary
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have been progressed after standard therapies, however, there has not been a predictive biomarker. The investigators designed this study to investigate whether \[18F\]FLT-PET might paly a role as a predictive imaging biomarker of treatment responses to regorafenib.
Study Details
Timeline
Interventions
Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.